Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...
Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% reduction in progression or death. The MajesTEC-9 trial highlights ...
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...
Radiation therapy could be an underused tool to reduce pelvic relapse risk for patients with locally advanced, muscle-invasive bladder cancer, according to results of a new phase III randomized trial.
BOSTON, Mass. (Ivanhoe Newswire) - CAR T-cell therapy has revolutionized the treatment of certain blood cancers — including leukemias, lymphomas and multiple myeloma. CAR T-cells are genetically ...
HBV, hepatitis B Researchers analyzed data from patients with chronic hepatitis B to identify predictors of relapse in those who discontinued NAs and determined if existing rules for stopping NA ...
Recovery from addiction is a challenging journey, filled with both triumphs and setbacks. For individuals seeking long-term sobriety, relapse can be a disheartening reality. However, recent findings ...
Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback